Clinical trial
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
NCT00333229 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00333229 |
|---|---|
| Title | A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss |
| Official title | Influence of Zoledronic Acid on Bone Mineral Density and Bone Ultrasonometry in Premenopausal Women With Hormone Receptor Negative Breast Cancer and Adjuvant Chemotherapeutic Treatment |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women |
| Intervention type | Drug |
| Interventions | Zoledronic Acid, Placebo |
| Enrollment | 11 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Jun 2, 2006 |
| Last update posted | Nov 25, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: